IP ALT-803 Followed by SQ ALT-803 for Ovarian Cancer

• ClinicalTrials.gov Identifier: NCT03054909
• Recruitment Status: Completed
• First Posted: February 16, 2017
• Last Update Posted: October 6, 2022
• Sponsor: Masonic Cancer Center, University of Minnesota
• Information provided by (Responsible Party): Masonic Cancer Center, University of Minnesota

Study Description

Brief Summary:

This is a single center, randomized phase II study of an IL-15Rα-Fc super-agonist complex (ALT-803) given as maintenance therapy after the completion of 1st line IV/IP chemotherapy for the treatment of advanced ovarian, fallopian tube, and primary peritoneal cancer.

Condition or disease	Intervention/treatment	Phase
FIGO Stage III and IV Ovarian Cancer; FIGO Stage III and IV Fallopian Tube Cancer; FIGO Stage III Primary Peritoneal Cancer	Biological: ALT-803 Subcutaneous; Biological: ALT-803 Intraperitoneal	Phase 2

Detailed Description:

In this study all patients receive four 8 week cycles of ALT-803 consisting of 4 weekly doses followed by a 4 week rest (no treatment). As it is not known how intraperitoneal (IP) administration (a route of drug administration frequently used for gynecologic cancers) of ALT-803 compares to subcutaneous (SQ) administration, both routes of administration will be tested. The primary objective of this trial is to select one method of delivery for further testing.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 7 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: QUILT-2.021: Randomized Study of Single Course of Intraperitoneal (IP) ALT-803 Followed by Subcutaneous (SQ) Maintenance ALT-803 Versus Subcutaneous (SQ) Maintenance ALT-803 Only After 1st Line Chemotherapy for Advanced Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
• Actual Study Start Date: September 19, 2017
• Actual Primary Completion Date: February 16, 2022
• Actual Study Completion Date: February 16, 2022

Arms and Interventions

Arm	Intervention/treatment
Experimental: Arm 1: ALT-803 subcutaneous only	Biological: ALT-803 Subcutaneous; Patient receives ALT-803 10 mcg/kg subcutaneous weekly x 4 followed by 4 weeks of no treatment before continuing with treatment courses 2, 3, and 4. Treatment courses 2, 3, and 4 are identical for all patients - ALT-803 10 mcg/kg subcutaneous weekly x 4 with a 4 week rest (4 weeks on/4 weeks off)
Experimental: Arm 2: ALT-803 intraperitoneal and subcutaneous	Biological: ALT-803 Intraperitoneal; Patient receives ALT-803 10 mcg/kg intraperitoneal weekly x 4 weeks followed by 4 weeks of no treatment before continuing with treatment courses 2, 3, and 4. Treatment courses 2, 3, and 4 are identical for all patients - ALT-803 10 mcg/kg subcutaneous weekly x 4 with a 4 week rest (4 weeks on/4 weeks off).

Outcome Measures

Primary Outcome Measures :

1. Progression Free Survival [ Time Frame: 6 months ]
   Incidence of Progression Free Survival

Secondary Outcome Measures :

1. Progression Free Survival [ Time Frame: 1 and 2 year ]
   Incidence of Progression Free Survival from start of ALT-803 dosing
2. Overall Survival [ Time Frame: 1 and 2 year ]
   Overall Survival from start of ALT-803 dosing
3. ALT-803 associated toxicities [ Time Frame: 1 year ]
   Incidence of ALT-803 associated toxicities
4. Incidence of no recorded toxicity grade 3 or greater [ Time Frame: 1 year ]
   The safety of ALT-803 will be documented by lack of grade 3 and greater toxicity.

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: Female
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria

• Diagnosis of FIGO stage III or grade IV epithelial ovarian, fallopian tube or primary peritoneal carcinoma, has received at least 3 cycles of first line IV/IP cisplatin and paclitaxel chemotherapy and has stable disease or better - refer to Appendix II for FIGO staging system (Note: to be eligible for this study, the patient must receive a minimum of 3 cycles of IP therapy; however, patients may continue on IV only 1st line therapy for additional cycles as long as inclusion criteria 4.1.2 is met)
• Able to begin study therapy within 3 months of final dose of first line chemotherapy
• Functioning intraperitoneal catheter
• ≥ 18 years of age
• GOG performance status ≤ 2 (Appendix II)

• Adequate organ function within 14 days of enrollment defined as:

  • Hematology: hemoglobin ≥ 8 g/dl, absolute neutrophil count (ANC) ≥ 1500/ul, platelets ≥ 50 x 109/L
  • Creatinine: ≤ 2.0 mg/dL
  • Hepatic: SGOT and SGPT ≤ 3 x upper limit of institutional normal (ULN)
• Ability to be off prednisone and other immunosuppressive drugs for at least 3 days prior to and while receiving ALT-803
• Voluntary written consent prior to the performance of any research related procedures

Exclusion Criteria

• Received any investigational agent within the 14 days before the start of ALT-803
• Class II or greater New York Heart Association Functional Classification criteria (Appendix II) or serious cardiac arrhythmias likely to increase the risk of cardiac complications of cytokine therapy (e.g. ventricular tachycardia, frequent ventricular ectopy, or supraventricular tachyarrhythmia requiring chronic therapy)
• Marked baseline prolongation of QT/QTc interval (e.g. demonstration of a QTc interval greater than 500 milliseconds)
• Uncontrolled bacterial, fungal or viral infections including HIV-1/2 or active hepatitis C/B - chronic asymptomatic viral hepatitis is allowed
• Active autoimmune disease requiring systemic immunosuppressive therapy
• History of severe asthma and currently on chronic systemic medications (mild asthma requiring inhaled steroids only is eligible)
• Uncontrolled hypertension: defined as ≥2 readings over 160 mmHg systolic or 110 mmHg diastolic within month prior to enrollment despite optimal anti-hypertensive medication. Patients with high readings which improve to ≤160/110 after adjustment of medications will be eligible.
• History of pulmonary disease or abnormal pulmonary function studies
• History of narcolepsy or any neurological condition which may impair consciousness

Contacts and Locations

Locations

United States, Minnesota

Masonic Cancer Center, University of Minnesota

Minneapolis, Minnesota, United States, 55455

Sponsors and Collaborators

Masonic Cancer Center, University of Minnesota

Investigators

• Principal Investigator: Melissa Geller, MD; University of Minnesota

More Information

• Responsible Party: Masonic Cancer Center, University of Minnesota
• ClinicalTrials.gov Identifier: NCT03054909
• Other Study ID Numbers: 2016LS034
• First Posted: February 16, 2017
• Last Update Posted: October 6, 2022
• Last Verified: October 2022

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No
• Product Manufactured in and Exported from the U.S.: No

Additional relevant MeSH terms:

Ovarian Neoplasms; Carcinoma, Ovarian Epithelial; Fallopian Tube Neoplasms; Endocrine Gland Neoplasms; Neoplasms by Site; Neoplasms; Ovarian Diseases; Adnexal Diseases; Genital Neoplasms, Female; Urogenital Neoplasms; Endocrine System Diseases; Gonadal Disorders; Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Fallopian Tube Diseases